OKYO Pharma Limited Announces Withdrawal of Public Offering
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced the withdrawal of its proposed public offering of ordinary shares and its termination of Freedom Capital Markets as underwriter. The decision was made in response to changing market conditions.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About OKYO Pharma
Keynote Presentation: How One City Got Smarter Using IoT
Government & Enterprise Using LoRaWAN for Logistics, Manufacturing, and Smart Refrigeration. How LoRAWAN Enables Regulation and Compliance
Todayâ€™s Reality: Protecting Businesses from Hackers, Ransomware, and Insider Threats